|
|
 |
|
|
|
|
|
|
What we are looking for
Oncology: Innovation and leadership.
An experienced and skilled partner.
We have a long history of working collaboratively -- to maximize the value of our products for our partners and for people living with cancer.
Global market leadership.
After more than forty years as a pioneer and innovator in discovering, developing, and bringing new therapies to patients with cancer, Bristol-Myers Squibb is still a global leader in oncology. We market about 20 medicines. We maintain a top sales force. We support professional societies and advocacy groups, giving us ties to the researchers, physicians, nurses, pharmacists, and patients.
Our pipeline of products in development includes innovative approaches to treating cancer. Through our efforts in the field of oncopharmacogenomics, we are gathering information about which patients are best equipped genetically to respond to these new drugs.
|
|
|
|
[Top Page] [Search]
[Index] [Contact] [Home]
Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Atripla is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.
© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy. |
|
|
